We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
About this guideline
Adopted by the TGA: 28 February 2020
Overseas effective date: 1 June 2000
Categories: ICH | Efficacy
Clinical efficacy and safety | Cardiovascular system | Hypertension
TGA annotations:
This ICH document describes core principles for the evaluation of antihypertensive. It should be considered an 'ICH principle document' rather than an 'ICH guideline'. The reader should also refer to the most recent TGA adopted guidelines on the treatment of hypertension.
- Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
- All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.
For more information see International scientific guidelines adopted in Australia.